Premium
Beta Human Chorionic Gonadotrophin in Serum and Urine. A Marker for Metastatic Urothelial Cancer
Author(s) -
ILES R. K.,
JENKINS B. J.,
OLIVER R. T. D.,
BLANDY J. P.,
CHARD T.
Publication year - 1989
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1989.tb06006.x
Subject(s) - urine , medicine , urology , cancer , urothelial carcinoma , bladder cancer , tumor marker , endocrinology , pathology
Summary— Beta human chorionic gonadotrophin (βHCG) was measured in 127 urine and 85 serum samples from 175 untreated patients with urothelial cancer. Serum levels of βHCG were substantially elevated in 16 of 21 patients (76%) with widespread metastases but in only 2 of 64 patients (3%) with disease confined to the pelvis. Urine βJHCG levels were moderately raised in 11 of 25 patients (44%) with locally advanced disease, but greatly elevated in 5 of 7 patients (71%) with metastases. Measurement of serum and/or urine βSHCG appears to be an efficient diagnostic marker for the presence of distant metastases in bladder carcinoma.